/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
SASKATOON, SK, Sept. 24, 2026 /CNW/ -- ZYUS Life Sciences Corporation (the "ZYUS" and or "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel drug product candidates for chronic pain is pleased to announce that it anticipates announcing topline results from its Phase 2a UTOPIA-1 clinical trial on September 30, 2026. In addition, the Company is pleased to announce the results of its Annual General and Special Meeting of Shareholders (the "Meeting") held on September 24, 2026, including the election of the Company's directors, the appointment of its external auditor and approval of its Omnibus Equity Incentive Plan. The Company further announces a change in the Chair of the Company's Audit Committee.
ZYUS Life Sciences Logo
Anticipated Timing of Phase 2a UTOPIA-1 Topline Results
The Company expects to announce topline results from its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial on September 30, 2026. The Phase 2a UTOPIA-1 trial evaluated Trichomylin® softgel capsules in patients experiencing moderate to severe cancer-related pain.
Annual General and Special Meeting Results and Appointment of External Auditor
At the Meeting, shareholders voted in favour of all matters presented for approval. Shareholders elected each of the nominees listed in the Company's management information circular dated August 14, 2026 as directors of the Company, with each director to hold office until the next annual meeting of shareholders or until their successor is duly elected or appointed. The Board of Directors (the "Board") continues to be comprised of six (6) directors: Brent H. Zettl, Richard Hoyt, John L. Knowles, Garnette Weber, Dr. Charlotte Moore Hepburn, and Wayne Brownlee.
Shareholders of the Company also approved the appointment of MNP LLP, Chartered Professional Accountants as external auditors of the Company and authorized the directors to fix the auditor's remuneration. In addition, shareholders also ratified, confirmed and approved the Company's Omnibus Equity Incentive Plan.
Change in Audit Committee Chair
The Company is also pleased to announce that Wayne Brownlee has been appointed Chair of the Audit Committee, replacing John L. Knowles, effective September 24, 2026.
Mr. Knowles was appointed Interim Chief Financial Officer of the Company effective September 14, 2026 and, in connection with his appointment, has stepped down as Chair of the Audit Committee. Mr. Knowles will continue to serve as a member of the Company's Board and as a member of the Audit Committee.